>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • PTON +14%, ZUMZ +8.6%, CNDT +5.5% (guidance), ORCL +3.5%, CX +2% (guidance), MSM +0.9%

Other news:

  • KODK +12.3% (Southeastern Asset Management discloses stake)
  • DQ +10.8% (announced that the application documents regarding a potential IPO of Xinjiang Daqo New Energy had been submitted to and received by the Shanghai Stock Exchange)
  • GLPG +8.8% (Phase 2a clinical trial with investigational ziritaxestat achieves primary endpoint)
  • RM +7% (reports 30+ day delinquencies remain stable at 4.6% in August, compared to 4.8% in June)
  • IMUX +6.7% (publishes full unblinded clinical data from Phase 2 emphasis trial of IMU-838 in patients with relapsing-remitting multiple sclerosis)
  • MNOV +5.8% (SARS-CoV-2 vaccine co-developer BioComo announced that its Respiratory Syncytial (RS) virus vaccine using BC-PIV technology induced high neutralizing antibodies in mice)
  • DKNG +3.7% (extends +5% gain from Thursday's regular session)
  • LYRA +3.2% (reports clinical data demonstrating LYR-210's local anti inflammatory effects for the treatment of chronic rhinosinusitis)
  • RIO +2.6% (CEO to step down; process to identify his successor is underway)
  • SLGL +1.3% (FDA accepts Epsolay NDA for filing)
  • GOGO +1.2% (comments on investment by GTCR)

Analyst comments:

  • PLAB +8.7% (upgraded to Buy from Hold at Stifel)
  • VSTO +4.6% (upgraded to Buy from Neutral at B. Riley FBR)
  • SPWR +3.8% (upgraded to Outperform from Neutral at Robert Baird)
  • LYB +3.7% (upgraded to Overweight from Neutral at JP Morgan)
  • ACMR +3.5% (upgraded to Buy from Hold at Stifel)
  • ADBE +3% (upgraded to Outperform from Market Perform at Cowen)
  • VIR +2.9% (upgraded to Neutral from Underweight at JP Morgan)
  • CTSH +1.8% (upgraded to Buy from Neutral at BofA Securities)
  • EQNR +1.7% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
  • DPZ +1.3% (upgraded to Outperform from Market Perform at Cowen)
  • TRV +1.1% (upgraded to Equal Weight from Underweight at Wells Fargo)
  • SWKS +1.1% (initiated with a Buy at Rosenblatt)